CO5011061A1 - Inhibicion de las metaloprotesas de matriz por acidos biariloxobutiricos sustituidos y composiciones farmaceuticas que los contienen - Google Patents
Inhibicion de las metaloprotesas de matriz por acidos biariloxobutiricos sustituidos y composiciones farmaceuticas que los contienenInfo
- Publication number
- CO5011061A1 CO5011061A1 CO97025174A CO97025174A CO5011061A1 CO 5011061 A1 CO5011061 A1 CO 5011061A1 CO 97025174 A CO97025174 A CO 97025174A CO 97025174 A CO97025174 A CO 97025174A CO 5011061 A1 CO5011061 A1 CO 5011061A1
- Authority
- CO
- Colombia
- Prior art keywords
- matrix
- metaloproteses
- biariloxobutiric
- inhibition
- acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/44—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/04—1,2,3-Triazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Inhibidores de la metaloproteinasa de matriz quetienen la fórmula general:donde r es 0-2, T es seleccionado entre el grupo que consiste eny R40 es seleccionado entre el grupo que consiste en y -CH2 OCH2 OCH2 Ph
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64849396A | 1996-05-15 | 1996-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5011061A1 true CO5011061A1 (es) | 2001-02-28 |
Family
ID=24601014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO97025174A CO5011061A1 (es) | 1996-05-15 | 1997-05-09 | Inhibicion de las metaloprotesas de matriz por acidos biariloxobutiricos sustituidos y composiciones farmaceuticas que los contienen |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP0923530B1 (es) |
JP (1) | JP3354942B2 (es) |
CN (1) | CN1100748C (es) |
AR (1) | AR007098A1 (es) |
AT (1) | ATE275123T1 (es) |
AU (1) | AU714207B2 (es) |
BR (1) | BR9709086A (es) |
CA (1) | CA2254731C (es) |
CO (1) | CO5011061A1 (es) |
DE (1) | DE69730508T2 (es) |
DK (1) | DK0923530T3 (es) |
ES (1) | ES2227696T3 (es) |
HK (1) | HK1021897A1 (es) |
HR (1) | HRP970244B1 (es) |
ID (1) | ID17291A (es) |
MY (1) | MY132463A (es) |
PA (1) | PA8429701A1 (es) |
PE (1) | PE66898A1 (es) |
PT (1) | PT923530E (es) |
SV (1) | SV1997000036A (es) |
TN (1) | TNSN97083A1 (es) |
TW (1) | TW539672B (es) |
WO (1) | WO1997043239A1 (es) |
YU (1) | YU18597A (es) |
ZA (1) | ZA974030B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5925637A (en) * | 1997-05-15 | 1999-07-20 | Bayer Corporation | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids |
US6288063B1 (en) | 1998-05-27 | 2001-09-11 | Bayer Corporation | Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors |
EP1031349A1 (en) * | 1999-02-25 | 2000-08-30 | Bayer Aktiengesellschaft | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases |
GB9922710D0 (en) * | 1999-09-24 | 1999-11-24 | Bayer Ag | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis |
PA8539401A1 (es) * | 2001-02-14 | 2002-10-28 | Warner Lambert Co | Quinazolinas como inhibidores de mmp-13 |
JP2004359546A (ja) * | 2001-03-15 | 2004-12-24 | Ono Pharmaceut Co Ltd | ヒドロキサム酸誘導体、それらの非毒性塩およびそれらのプロドラッグ体を有効成分として含有する、固形癌の予防および/または治療剤 |
JPWO2002074298A1 (ja) * | 2001-03-21 | 2004-07-08 | 小野薬品工業株式会社 | Il−6産生阻害剤 |
KR101405823B1 (ko) * | 2007-12-24 | 2014-06-12 | 주식회사 케이티앤지생명과학 | 녹내장의 치료 및 예방을 위한 약제 조성물 |
KR20090071829A (ko) * | 2007-12-28 | 2009-07-02 | 주식회사 머젠스 | 신장질환의 치료 및 예방을 위한 약제 조성물 |
US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
BRPI0917394A2 (pt) * | 2008-08-18 | 2019-09-24 | Univ Yale | moduladores de mif |
CN106458938A (zh) | 2014-04-03 | 2017-02-22 | 拜耳制药股份公司 | 手性2,5‑二取代的环戊烷甲酸衍生物及其用途 |
US20170022171A1 (en) | 2014-04-03 | 2017-01-26 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituted cyclopentanecarboxylic acids and their use |
US20170114049A1 (en) * | 2014-04-03 | 2017-04-27 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratory tract diseases |
CN113979992B (zh) * | 2021-11-19 | 2022-06-24 | 西安欧得光电材料有限公司 | 一种3-取代二苯并噻吩及其合成方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU678884B2 (en) * | 1994-01-22 | 1997-06-12 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
-
1997
- 1997-05-09 HR HR970244A patent/HRP970244B1/xx not_active IP Right Cessation
- 1997-05-09 TN TNTNSN97083A patent/TNSN97083A1/fr unknown
- 1997-05-09 ZA ZA9704030A patent/ZA974030B/xx unknown
- 1997-05-09 MY MYPI97002043A patent/MY132463A/en unknown
- 1997-05-09 CO CO97025174A patent/CO5011061A1/es unknown
- 1997-05-12 CA CA002254731A patent/CA2254731C/en not_active Expired - Fee Related
- 1997-05-12 JP JP54100397A patent/JP3354942B2/ja not_active Expired - Fee Related
- 1997-05-12 AU AU31220/97A patent/AU714207B2/en not_active Ceased
- 1997-05-12 PE PE1997000365A patent/PE66898A1/es not_active Application Discontinuation
- 1997-05-12 DK DK97926455T patent/DK0923530T3/da active
- 1997-05-12 PA PA19978429701A patent/PA8429701A1/es unknown
- 1997-05-12 DE DE69730508T patent/DE69730508T2/de not_active Expired - Fee Related
- 1997-05-12 ES ES97926455T patent/ES2227696T3/es not_active Expired - Lifetime
- 1997-05-12 PT PT97926455T patent/PT923530E/pt unknown
- 1997-05-12 AR ARP970101978A patent/AR007098A1/es unknown
- 1997-05-12 BR BR9709086A patent/BR9709086A/pt not_active Application Discontinuation
- 1997-05-12 WO PCT/US1997/007976 patent/WO1997043239A1/en active IP Right Grant
- 1997-05-12 SV SV1997000036A patent/SV1997000036A/es not_active Application Discontinuation
- 1997-05-12 TW TW086106285A patent/TW539672B/zh not_active IP Right Cessation
- 1997-05-12 EP EP97926455A patent/EP0923530B1/en not_active Expired - Lifetime
- 1997-05-12 YU YU18597A patent/YU18597A/sh unknown
- 1997-05-12 CN CN97196454A patent/CN1100748C/zh not_active Expired - Fee Related
- 1997-05-12 AT AT97926455T patent/ATE275123T1/de not_active IP Right Cessation
- 1997-05-14 ID IDP971611A patent/ID17291A/id unknown
-
2000
- 2000-02-10 HK HK00100770A patent/HK1021897A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE69730508T2 (de) | 2005-09-29 |
TW539672B (en) | 2003-07-01 |
CN1100748C (zh) | 2003-02-05 |
PA8429701A1 (es) | 2000-05-24 |
EP0923530A1 (en) | 1999-06-23 |
ES2227696T3 (es) | 2005-04-01 |
PE66898A1 (es) | 1998-10-22 |
TNSN97083A1 (fr) | 2005-03-15 |
SV1997000036A (es) | 1998-07-20 |
ATE275123T1 (de) | 2004-09-15 |
AR007098A1 (es) | 1999-10-13 |
JP3354942B2 (ja) | 2002-12-09 |
EP0923530B1 (en) | 2004-09-01 |
BR9709086A (pt) | 1999-08-03 |
HRP970244B1 (en) | 2005-06-30 |
ID17291A (id) | 1997-12-18 |
YU18597A (sh) | 2001-12-26 |
ZA974030B (en) | 1998-02-19 |
HRP970244A2 (en) | 1998-04-30 |
CA2254731C (en) | 2004-07-20 |
MY132463A (en) | 2007-10-31 |
DE69730508D1 (de) | 2004-10-07 |
PT923530E (pt) | 2004-12-31 |
CA2254731A1 (en) | 1997-11-20 |
HK1021897A1 (en) | 2000-07-14 |
DK0923530T3 (da) | 2005-01-03 |
AU714207B2 (en) | 1999-12-23 |
JPH11510821A (ja) | 1999-09-21 |
WO1997043239A1 (en) | 1997-11-20 |
AU3122097A (en) | 1997-12-05 |
CN1225621A (zh) | 1999-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5011061A1 (es) | Inhibicion de las metaloprotesas de matriz por acidos biariloxobutiricos sustituidos y composiciones farmaceuticas que los contienen | |
RU95104885A (ru) | 1h-индол-3-глиоксиламиды, ингибирующие spla2-медируемое выделение жирных кислот, фармацевтическая композиция | |
ES2136037B1 (es) | Inhibidores de sulfamida-metaloproteasa | |
BR0010555A (pt) | Inibidores de neuraminidases | |
FI971412A0 (fi) | Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasien estäjinä | |
ATE241998T1 (de) | Multikatalytische protease-inhibitoren | |
AR023289A1 (es) | COMPUESTOS CON ACTIVIDAD INHIBIDORA DE ENDOPEPTIDASA NEUTRA (NEP), COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE, Y PROCEDIMIENTO PARA SU PREPARACIoN. | |
NO991494L (no) | <beta>-sulfonylhydroksaminsyrer som matriksmetalloproteinaseinhibitorer | |
DK0840732T3 (da) | Substituerede benzolactamforbindelser som substans P-antagonister | |
AR008377A1 (es) | Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto | |
ES2137836B1 (es) | Composicion de recubrimiento inhibidora de corrosion para metales. | |
AR009358A1 (es) | Compuesto espirociclico inhibidor de la metaloproteasa | |
FI943728A0 (fi) | Enkefalinaasin ja ACE:n inhibiittoreina käyttökelpoisia uusia aminoasetyylimerkaptojohdannaisia | |
FI963169A0 (fi) | Enkefalinaasin ja ACE:n inhibittoreina käyttökelpoisia uusia merkaptoasetyyliamido-1,3,4,5-tetrahydrobents/c/-atsepin-3-onidisulfidijohdannaisia | |
AR018186A1 (es) | Compuestos de carbazoly de 1,2,3,4-tetrahidrocarbazol sustituidos, utiles como inhibidores de la liberacion de acidos grasos mediada por spla2,procedimiento para prepararlos; compuestos intermediarios de aplicacion en dichos procedimientos; composiciones farmaceuticas que comprenden dichos compuesto | |
AR002690A1 (es) | Derivado de bencimidazol o sales del mismo, composicion farmaceutica, agente inmunosupresor y agente antiinflamatorio que lo contienen yprocedimientos para preparar dicho derivado. | |
FI915093A0 (fi) | Sackarinderivat anvaendbara som inhibitorer foer proteolytiskt enzym och deras framstaellning. | |
MX9305364A (es) | Compuestos inhibidores de proteasa retroviral, metodo para su produccion y composicion farmaceutica que los comprende. | |
AR008621A1 (es) | Un compuesto derivado de amina succinica, un procedimiento para llevar a cabo su preparacion y una composicion farmaceutica que comprende dichocompuesto | |
ES2159347T3 (es) | Naftil-acetamidas como inhibidores de spla2. | |
CA2266759A1 (en) | 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase | |
EE03745B1 (et) | Asendatud 4-bifenüül-4-hüdroksübutaanhappe derivaadid metalloproteaasimaatriksi inhibiitoritena | |
DK0656001T3 (da) | Nye 2-substituerede indan-2-mercaptoacetylamid-tricycliske derivater til anvendelse som enkefalinasehæmmere | |
RU94038042A (ru) | Производные гексагидроазепинов, фармацевтическая композиция на их основе и антипсихотропный агент | |
ES2192263T3 (es) | Derivados de benzo(c)quinolizina, su preparacion y empleo como inhibidores de 5-alfa-reductasas. |